Veru (NASDAQ:VERU) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Shares of Veru Inc. (NASDAQ:VERU) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.74 and traded as low as $2.30. Veru shares last traded at $2.40, with a volume of 95,936 shares changing hands.

Analyst Ratings Changes

Several research firms recently issued reports on VERU. Oppenheimer restated an “outperform” rating on shares of Veru in a report on Thursday, December 18th. Canaccord Genuity Group began coverage on shares of Veru in a report on Thursday, December 18th. They issued a “buy” rating and a $25.00 target price on the stock. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Veru in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Trading Up 4.8%

The company has a market cap of $38.52 million, a P/E ratio of -1.90 and a beta of -1.35. The stock’s 50-day moving average price is $2.41 and its 200-day moving average price is $2.74.

Veru (NASDAQ:VERU) last released its quarterly earnings data on Wednesday, February 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.21. On average, research analysts anticipate that Veru Inc. will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veru

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Veru in the 3rd quarter worth about $38,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Veru in the 3rd quarter worth about $47,000. XTX Topco Ltd acquired a new stake in shares of Veru in the 2nd quarter worth about $49,000. ADAR1 Capital Management LLC acquired a new stake in shares of Veru in the 4th quarter worth about $75,000. Finally, Blair William & Co. IL raised its holdings in shares of Veru by 26.3% in the 4th quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock worth $103,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.